BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

510 related articles for article (PubMed ID: 11502801)

  • 1. Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients.
    Toft-Nielsen MB; Damholt MB; Madsbad S; Hilsted LM; Hughes TE; Michelsen BK; Holst JJ
    J Clin Endocrinol Metab; 2001 Aug; 86(8):3717-23. PubMed ID: 11502801
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus.
    Nauck MA; Heimesaat MM; Orskov C; Holst JJ; Ebert R; Creutzfeldt W
    J Clin Invest; 1993 Jan; 91(1):301-7. PubMed ID: 8423228
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Determinants of the effectiveness of glucagon-like peptide-1 in type 2 diabetes.
    Toft-Nielsen MB; Madsbad S; Holst JJ
    J Clin Endocrinol Metab; 2001 Aug; 86(8):3853-60. PubMed ID: 11502823
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Incretin secretion in relation to meal size and body weight in healthy subjects and people with type 1 and type 2 diabetes mellitus.
    Vilsbøll T; Krarup T; Sonne J; Madsbad S; Vølund A; Juul AG; Holst JJ
    J Clin Endocrinol Metab; 2003 Jun; 88(6):2706-13. PubMed ID: 12788877
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Glucagonostatic actions and reduction of fasting hyperglycemia by exogenous glucagon-like peptide I(7-36) amide in type I diabetic patients.
    Creutzfeldt WO; Kleine N; Willms B; Orskov C; Holst JJ; Nauck MA
    Diabetes Care; 1996 Jun; 19(6):580-6. PubMed ID: 8725855
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The pathophysiology of diabetes involves a defective amplification of the late-phase insulin response to glucose by glucose-dependent insulinotropic polypeptide-regardless of etiology and phenotype.
    Vilsbøll T; Knop FK; Krarup T; Johansen A; Madsbad S; Larsen S; Hansen T; Pedersen O; Holst JJ
    J Clin Endocrinol Metab; 2003 Oct; 88(10):4897-903. PubMed ID: 14557471
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients.
    Vilsbøll T; Krarup T; Deacon CF; Madsbad S; Holst JJ
    Diabetes; 2001 Mar; 50(3):609-13. PubMed ID: 11246881
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predictors of incretin concentrations in subjects with normal, impaired, and diabetic glucose tolerance.
    Vollmer K; Holst JJ; Baller B; Ellrichmann M; Nauck MA; Schmidt WE; Meier JJ
    Diabetes; 2008 Mar; 57(3):678-87. PubMed ID: 18057091
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gut incretin hormones in identical twins discordant for non-insulin-dependent diabetes mellitus (NIDDM)--evidence for decreased glucagon-like peptide 1 secretion during oral glucose ingestion in NIDDM twins.
    Vaag AA; Holst JJ; Vølund A; Beck-Nielsen HB
    Eur J Endocrinol; 1996 Oct; 135(4):425-32. PubMed ID: 8921824
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Normal secretion and action of the gut incretin hormones glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide in young men with low birth weight.
    Schou JH; Pilgaard K; Vilsbøll T; Jensen CB; Deacon CF; Holst JJ; Vølund A; Madsbad S; Vaag AA
    J Clin Endocrinol Metab; 2005 Aug; 90(8):4912-9. PubMed ID: 15899957
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hormonal Responses to Cholinergic Input Are Different in Humans with and without Type 2 Diabetes Mellitus.
    Chowdhury S; Wang S; Dunai J; Kilpatrick R; Oestricker LZ; Wallendorf MJ; Patterson BW; Reeds DN; Wice BM
    PLoS One; 2016; 11(6):e0156852. PubMed ID: 27304975
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Twenty-four-hour insulin secretion rates, circulating concentrations of fuel substrates and gut incretin hormones in healthy offspring of Type II (non-insulin-dependent) diabetic parents: evidence of several aberrations.
    Nyholm B; Walker M; Gravholt CH; Shearing PA; Sturis J; Alberti KG; Holst JJ; Schmitz O
    Diabetologia; 1999 Nov; 42(11):1314-23. PubMed ID: 10550415
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Insulin secretion and incretin hormones after oral glucose in non-obese subjects with impaired glucose tolerance.
    Rask E; Olsson T; Söderberg S; Holst Jj Jj; Tura A; Pacini G; Ahrén B
    Metabolism; 2004 May; 53(5):624-31. PubMed ID: 15131768
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Shape of the Glucose Response Curve During an Oral Glucose Tolerance Test Heralds Biomarkers of Type 2 Diabetes Risk in Obese Youth.
    Kim JY; Michaliszyn SF; Nasr A; Lee S; Tfayli H; Hannon T; Hughan KS; Bacha F; Arslanian S
    Diabetes Care; 2016 Aug; 39(8):1431-9. PubMed ID: 27293201
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Both GLP-1 and GIP are insulinotropic at basal and postprandial glucose levels and contribute nearly equally to the incretin effect of a meal in healthy subjects.
    Vilsbøll T; Krarup T; Madsbad S; Holst JJ
    Regul Pept; 2003 Jul; 114(2-3):115-21. PubMed ID: 12832099
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans.
    Nauck MA; Niedereichholz U; Ettler R; Holst JJ; Orskov C; Ritzel R; Schmiegel WH
    Am J Physiol; 1997 Nov; 273(5):E981-8. PubMed ID: 9374685
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization of beta-cell function impairment in first-degree relatives of type 2 diabetic subjects: modeling analysis of 24-h triple-meal tests.
    Mari A; Gastaldelli A; Natali A; Ostergard T; Schmitz O; Ferrannini E
    Am J Physiol Endocrinol Metab; 2005 Mar; 288(3):E541-6. PubMed ID: 15522997
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pancreas and gut hormone responses to oral glucose and intravenous glucagon in cystic fibrosis patients with normal, impaired, and diabetic glucose tolerance.
    Lanng S; Thorsteinsson B; Røder ME; Orskov C; Holst JJ; Nerup J; Koch C
    Acta Endocrinol (Copenh); 1993 Mar; 128(3):207-14. PubMed ID: 8480468
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The glucose dependent insulinotropic polypeptide response to oral glucose and mixed meals is increased in patients with type 2 (non-insulin-dependent) diabetes mellitus.
    Jones IR; Owens DR; Luzio S; Williams S; Hayes TM
    Diabetologia; 1989 Sep; 32(9):668-77. PubMed ID: 2676668
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enhanced glucagon-like peptide-1 (GLP-1) response to oral glucose in glucose-intolerant HIV-infected patients on antiretroviral therapy.
    Andersen O; Haugaard SB; Holst JJ; Deacon CF; Iversen J; Andersen UB; Nielsen JO; Madsbad S
    HIV Med; 2005 Mar; 6(2):91-8. PubMed ID: 15807714
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.